Cargando…
NO SAFETY CONCERNS OBSERVED WHEN THE ADJUVANTED RECOMBINANT ZOSTER VACCINE (RZV) AND THE COVID-19 MRNA-1273 BOOSTER WERE CO-ADMINISTERED IN ≥50-YEAR-OLDS
INTRO: The US CDC recommends that COVID-19 vaccines may be coadministered with other age-appropriate vaccines. There is limited data assessing outcomes, including reactogenicity, on such co-administration. For the first time, we present interim safety data of RZV administered concomitantly or sequen...
Autores principales: | Naficy, A., Pirrotta, P., Kuxhausen, A., Miller, J., Leav, B., Mwakingwe-Omari, A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Ltd.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186933/ http://dx.doi.org/10.1016/j.ijid.2023.04.139 |
Ejemplares similares
-
No Immunological Interference or Safety Concerns When Adjuvanted Recombinant Zoster Vaccine Is Coadministered With a Coronavirus Disease 2019 mRNA-1273 Booster Vaccine in Adults Aged 50 Years and Older: A Randomized Trial
por: Naficy, Abdi, et al.
Publicado: (2023) -
114. Long-term Protection Against Herpes Zoster (HZ) by the Adjuvanted Recombinant Zoster Vaccine (RZV): Interim Efficacy, Immuno and Safety Results at Approximately 10 Years after Initial Vaccination
por: Strezova, Ana, et al.
Publicado: (2022) -
8. The Adjuvanted Recombinant Zoster Vaccine (RZV) Confers Long-term Protection Against Herpes Zoster: Interim Results of an Extension Study (ZOSTER-049) of Two Clinical Trials (ZOE-50 and ZOE-70)
por: Boutry, Céline, et al.
Publicado: (2020) -
08. Concomitant Administration of the Adjuvanted Recombinant Zoster Vaccine (RZV) with 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Is Safe and Does Not Interfere with Immunogenicity of Either Vaccine in Adults Aged ≥ 50 Years
por: Min, Ji-Young, et al.
Publicado: (2021) -
Recombinant zoster vaccine in immunocompetent and immunocompromised adults: A review of clinical studies
por: Mwakingwe-Omari, Agnes, et al.
Publicado: (2023)